Court idles Sun-Ranbaxy deal

Share this article:

Insider-trading allegations have temporarily halted the Sun-Ranbaxy merger. The Wall Street Journal reports a court put a halt to the $3-billion merger until after an investigation. The move means Daiichi Sankyo, owner of Ranbaxy, may have to hold onto its 65% ownership stake a little longer.

The attempted sell-off follows a series of regulatory missteps that exacted harsh measures, including the FDA banning products from four of Ranbaxy's sites.

While Daiichi Sankyo would no longer own Ranbaxy, the purchase agreement would give the company a 9% stake in the new Sun-Ranbaxy company.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters